The Lancet6h
Spillover benefits of workforce capacity building in radiotherapy
The 2024 GLOBOCAN report highlights a projected increase in the global burden of cancer from 20 million new diagnoses in 2022, to 35 million in 2050.1 Radiotherapy and theranostics: a Lancet Oncology ...
The Lancet7h
Radiotherapy and conflict: from disruption to expansion and hope
Radiotherapy and theranostics are crucial in cancer management, with more than 50% of patients with cancer needing ...
The Lancet7h
Radiotherapy gaps and new frontiers in the Commonwealth
In 2015, the Lancet Oncology Commission on expanding global access to radiotherapy laid out the first evidence-based case for global investment in radiotherapy by showing substantial health and ...
The Lancet7h
Focus where it matters: turning insights into advocacy
The 2015 Lancet Oncology Commission on expanding global access to radiotherapy1 was a pivotal moment in global oncology. It highlighted disparities in radiotherapy access and revealed radiotherapy ...